[Effect of alpha-difluoromethylornithine on growth characteristics and expression of ALT-04ag gene of human lung carcinoma cells]. 2002

Zhi-hua Chen, and Hai-ping Ke, and Hong-yan Li, and Qing Fang, and Shu-lan Cao, and Mu-zhen Fan
Department of Biochemistry and Molecular Biology, China-Japan Friendship Hospital, China-Japan Friendship Institute of Clinical Medical Science, Beijing 100029, China. chzhihua@sina.com

OBJECTIVE To study the effect of polyamine biosynthesis inhibition on growth characteristics of human lung carcinoma cells and its correlation with the expression of human lung carcinoma associated antigen ALT-04ag gene. METHODS The gene expression was detected by RT-PCR and immunocytochemical tests. The cell growth characteristics were studied by cell growth curves, morphological observation, FCM analysis and DNA electrophoresis. RESULTS Human lung squamous carcinoma cells L78 treated with 5 mmol/L alpha-difluoromethylornithine (DFMO) for 5 days showed significant growth inhibition and apoptosis induction. The mRNA and protein expressions of ALT-04ag gene in the cells were downregulated, while these changes resulted from DFMO treatment were prevented by provision of DFMO along with exogenous putrescine. CONCLUSIONS The effect of polyamine biosynthesis inhibition induced by DFMO restrains the growth characteristics and promotes apoptosis of human lung carcinoma L78 cells, which is associated with down regulation of ALT-04ag gene expression.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000518 Eflornithine An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway. Difluoromethylornithine,alpha-Difluoromethylornithine,DL-alpha-Difluoromethylornithine,Eflornithine Hydrochloride,Eflornithine Monohydrochloride, Monohydrate,MDL-71,782 A,Ornidyl,RMI 71782,Vaniqa,alpha-Difluoromethyl Ornithine,DL alpha Difluoromethylornithine,MDL 71,782 A,MDL71,782 A,Ornithine, alpha-Difluoromethyl,alpha Difluoromethyl Ornithine,alpha Difluoromethylornithine
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D015513 Oncogene Proteins Proteins coded by oncogenes. They include proteins resulting from the fusion of an oncogene and another gene (ONCOGENE PROTEINS, FUSION). Oncogene Products,Oncoprotein,Oncoproteins,Oncogene Product,Oncogene Protein,Product, Oncogene,Products, Oncogene,Protein, Oncogene,Proteins, Oncogene
D015536 Down-Regulation A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Down-Regulation,Down-Regulation (Physiology),Downregulation,Down Regulation,Down-Regulation, Receptor

Related Publications

Zhi-hua Chen, and Hai-ping Ke, and Hong-yan Li, and Qing Fang, and Shu-lan Cao, and Mu-zhen Fan
January 1988, European journal of gynaecological oncology,
Zhi-hua Chen, and Hai-ping Ke, and Hong-yan Li, and Qing Fang, and Shu-lan Cao, and Mu-zhen Fan
August 1982, Cancer research,
Zhi-hua Chen, and Hai-ping Ke, and Hong-yan Li, and Qing Fang, and Shu-lan Cao, and Mu-zhen Fan
April 1986, Cancer research,
Zhi-hua Chen, and Hai-ping Ke, and Hong-yan Li, and Qing Fang, and Shu-lan Cao, and Mu-zhen Fan
January 1986, Acta biochimica et biophysica Hungarica,
Zhi-hua Chen, and Hai-ping Ke, and Hong-yan Li, and Qing Fang, and Shu-lan Cao, and Mu-zhen Fan
November 2003, Ai zheng = Aizheng = Chinese journal of cancer,
Zhi-hua Chen, and Hai-ping Ke, and Hong-yan Li, and Qing Fang, and Shu-lan Cao, and Mu-zhen Fan
October 1986, Journal of interferon research,
Zhi-hua Chen, and Hai-ping Ke, and Hong-yan Li, and Qing Fang, and Shu-lan Cao, and Mu-zhen Fan
April 1983, European journal of cancer & clinical oncology,
Zhi-hua Chen, and Hai-ping Ke, and Hong-yan Li, and Qing Fang, and Shu-lan Cao, and Mu-zhen Fan
July 1986, International journal of cancer,
Zhi-hua Chen, and Hai-ping Ke, and Hong-yan Li, and Qing Fang, and Shu-lan Cao, and Mu-zhen Fan
June 2006, Zhongguo fei ai za zhi = Chinese journal of lung cancer,
Zhi-hua Chen, and Hai-ping Ke, and Hong-yan Li, and Qing Fang, and Shu-lan Cao, and Mu-zhen Fan
May 2001, Toxicological sciences : an official journal of the Society of Toxicology,
Copied contents to your clipboard!